Could mounjaro ease heart failure in obesity? new trial investigates
NCT ID NCT07554638
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether tirzepatide (Mounjaro), a drug used for diabetes and weight loss, can help people with obesity-related heart failure with preserved ejection fraction (HFpEF). Researchers will measure changes in blood volume and body fat in 50 participants over 15 months. The goal is to understand how tirzepatide might improve heart function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tirzepatide (Mounjaro)
- What this could lead to
- If successful, this could show that tirzepatide improves heart failure symptoms in people with obesity by lowering blood volume, pointing toward a new treatment approach.
- What could go wrong
- This is a small, early-phase study with only 50 participants, so results may not apply to everyone. It focuses on measuring changes in blood volume, not directly on symptoms or survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?